title: New evidence for coupled clock regulation of the normal automaticity of sinoatrial nodal pacemaker cells: bradycardic effects of ivabradine are linked to suppression of intracellular Ca²⁺ cycling.
abstract: Beneficial clinical bradycardic effects of ivabradine (IVA) have been interpreted solely on the basis of If inhibition, because IVA specifically inhibits If in sinoatrial nodal pacemaker cells (SANC). However, it has been recently hypothesized that SANC normal automaticity is regulated by crosstalk between an "M clock," the ensemble of surface membrane ion channels, and a "Ca(2+) clock," the sarcoplasmic reticulum (SR). We tested the hypothesis that crosstalk between the two clocks regulates SANC automaticity, and that indirect suppression of the Ca(2+) clock further contributes to IVA-induced bradycardia. IVA (3 μM) not only reduced If amplitude by 45 ± 6% in isolated rabbit SANC, but the IVA-induced slowing of the action potential (AP) firing rate was accompanied by reduced SR Ca(2+) load, slowed intracellular Ca(2+) cycling kinetics, and prolonged the period of spontaneous local Ca(2+) releases (LCRs) occurring during diastolic depolarization. Direct and specific inhibition of SERCA2 by cyclopiazonic acid (CPA) had effects similar to IVA on LCR period and AP cycle length. Specifically, the LCR period and AP cycle length shift toward longer times almost equally by either direct perturbations of the M clock (IVA) or the Ca(2+) clock (CPA), indicating that the LCR period reports the crosstalk between the clocks. Our numerical model simulations predict that entrainment between the two clocks that involves a reduction in INCX during diastolic depolarization is required to explain the experimentally AP firing rate reduction by IVA. In summary, our study provides new evidence that a coupled-clock system regulates normal cardiac pacemaker cell automaticity. Thus, IVA-induced bradycardia includes a suppression of both clocks within this system.
authors: Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, 5600 Nathan Shock Dr., Baltimore, MD 21224, USA.
authors: Yael
authors: Y
authors: Yaniv
authors: Syevda
authors: S
authors: Sirenko
authors: Bruce D
authors: BD
authors: Ziman
authors: Harold A
authors: HA
authors: Spurgeon
authors: Victor A
authors: VA
authors: Maltsev
authors: Edward G
authors: EG
authors: Lakatta
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D001919:Bradycardia / Q000139:chemically induced*; D002118:Calcium / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D000077550:Ivabradine; D008954:Models, Biological; D008962:Models, Theoretical; D011817:Rabbits; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D012849:Sinoatrial Node / Q000166:cytology* / Q000187:drug effects
chemical_list: D001552:Benzazepines; D007211:Indoles; D000077550:Ivabradine; D002118:Calcium; C000543:cyclopiazonic acid
keywords: 50% decay time of intracellular Ca(2+); 90% decay time of intracellular Ca(2+); AC; AP; Action potential; Adenylyl-cyclases; CPA; Ca(2+) cycling; Cyclopiazonic acid; IVA; Ion channels; Ivabradine; LCR; Local Ca(2+) release; M; MDP; Maximum diastolic depolarization; Membrane; PKA; PLB; Phospholamban; Physiology; Protein kinase A; SANC; SR; Sarcoplasmic reticulum; Sinoatrial nodal pacemaker cells; Sinoatrial-node cells; T-50(c); T-90(c)
references: Circ Res. 2002 Jan 11;90(1):73-9
references: 11786521
references: Circ J. 2012;76(2):309-16
references: 22094913
references: Br J Pharmacol. 1994 May;112(1):37-42
references: 8032660
references: J Clin Invest. 2010 Dec;120(12):4388-98
references: 21099118
references: Molecules. 2012 Jul 09;17(7):8241-54
references: 22777191
references: Br J Pharmacol. 1996 Jun;118(4):1051-7
references: 8799581
references: Circ Res. 2001 Jun 22;88(12):1254-8
references: 11420301
references: Sci Am. 1993 Dec;269(6):102-9
references: 8266056
references: Int J Cardiol. 2011 Sep 1;151(2):218-24
references: 21764469
references: J Physiol. 1996 Nov 1;496 ( Pt 3):795-808
references: 8930845
references: Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2010-23
references: 20228256
references: Cardiovasc Res. 2005 Dec 1;68(3):366-75
references: 16226237
references: Circ Res. 2007 Jun 22;100(12):1723-31
references: 17525366
references: Br J Pharmacol. 1995 Jul;115(5):787-94
references: 8548178
references: Circulation. 1998 Apr 28;97(16):1623-31
references: 9593568
references: J Physiol. 2012 Sep 15;590(18):4483-99
references: 22711956
references: Cardiology. 2010;117(3):234-42
references: 21212673
references: Nature. 1991 May 9;351(6322):145-7
references: 1709448
references: Circ Res. 2010 Sep 17;107(6):767-75
references: 20651285
references: Circ Res. 2010 Mar 5;106(4):659-73
references: 20203315
references: J Gen Physiol. 2002 Jul;120(1):1-13
references: 12084770
references: Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H493-4
references: 19525376
references: PLoS One. 2012;7(5):e37582
references: 22666369
references: Expert Opin Pharmacother. 2011 Feb;12(3):443-50
references: 21254949
references: Eur Heart J. 2008 Sep;29(18):2265-75
references: 18621770
references: Circ Res. 2006 Mar 3;98(4):505-14
references: 16424365
references: J Mol Cell Cardiol. 2010 Jul;49(1):33-40
references: 20380837